Eli Lilly's retatrutide shows groundbreaking results in Type 2 diabetes trial
Eli Lilly's retatrutide shows groundbreaking results in Type 2 diabetes trial
Eli Lilly's retatrutide shows groundbreaking results in Type 2 diabetes trial
Eli Lilly's experimental drug retatrutide has shown strong results in its first major trial. The treatment helped Type 2 diabetes patients reduce blood sugar levels significantly more than a placebo. Participants also saw notable weight loss at higher doses.
The Phase 3 study tested retatrutide over 40 weeks in patients with Type 2 diabetes. Those taking the drug achieved HbA1c reductions of 1.7% to 2%, compared to just 0.8% in the placebo group. Weight loss reached up to 16.8% at the highest dose.
Unlike some competitors, retatrutide works on three hormone pathways: GLP-1, GIP, and glucagon. Most similar drugs target only one or two receptors. Lilly has not yet submitted the treatment for regulatory approval but expects more data soon. The company plans to release findings from six additional Phase 3 trials in 2026. These will cover obesity, cardiovascular disease, chronic kidney disease, and knee osteoarthritis. Further details on obesity-related osteoarthritis studies are also expected next year.
Retatrutide's early success in lowering blood sugar and aiding weight loss marks a promising step. Regulatory decisions will depend on upcoming trial results across multiple conditions. Lilly aims to complete key studies before the end of 2026.